Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinson’s disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial

医学 阶段(地层学) 中医药 血瘀 安慰剂 疾病 内科学 随机对照试验 临床试验 物理疗法 替代医学 病理 古生物学 生物
作者
Yuqing Hu,Si-Chun Gu,Xiaolei Yuan,Hui Li,Can-Xing Yuan,Qing Ye
出处
期刊:Chinese Medicine [Springer Nature]
卷期号:17 (1) 被引量:2
标识
DOI:10.1186/s13020-022-00625-4
摘要

Abstract Background Parkinson’s disease (PD) is a progressive neurodegenerative disease common in aged populations. Classified by Hoehn & Yahr stages, patients are often divided into mild/early stage, moderate/middle stage, and advanced/late stage. With disease progression, PD shows high heterogeneity in each stage. Based on traditional Chinese medicine (TCM) syndrome differentiation theory and our previous works, we found that during the early stage, the main syndrome is Yin deficiency of the liver and kidney; during the moderate stage, the main syndromes are phlegm heat and wind stirring and blood stasis and wind stirring; and during the late stage, the dominant syndromes are deficiency of Yin and Yang and deficiency of Qi and blood. Hence, we proposed a new model of TCM treatment by the stage of PD. Based on Shudi Pingchan formula, an experimental formula of our team, we developed Ziyin Pingchan formula, Jiedu Pingchan formula, and Fuzheng Pingchan formula to treat each stage. This study is designed to evaluate the therapeutic effect of treating Parkinson’s disease by stages using traditional Chinese medicine and to provide an evidence base for forming a standardized scheme of diagnosis and treatment. Methods This study is designed as a multicentre, randomized, double-blind, placebo-controlled clinical trial. Patients will be stratified into 3 subgroups according to Hoehn & Yahr stage; 172, 168, and 72 participants will be required to be in the mild PD, moderate PD, and advanced PD subgroups, respectively, and will be randomized into the treatment or control group at a 1:1 ratio. The mild PD subgroup will receive a 48-week intervention, and the other 2 groups will receive a 24-week intervention. All groups will have a follow-up visit 12 weeks after starting the intervention. The intervention group will receive the Ziyin Pingchan formula, Jiedu Pingchan formula, or Fuzheng Pingchan formula, and the control group will receive the corresponding placebo. The primary outcomes will be the first addition of levodopa for the mild PD subgroup, the duration of the “OFF” period for the moderate PD subgroup, and the Parkinson's Disease Questionnaire (PDQ-39) for the advanced PD subgroup. The secondary outcomes will also be verified by subgroups, including the Unified Parkinson’s Disease Rating Scale (UPDRS), Parkinson’s Disease Sleep Scale-2 (PDSS-2), scales for Outcomes in Parkinson’s Disease—Autonomic (SCOPA-AUT), and the nonmotor symptom scale (NMSS). Expected outcomes To our knowledge, this is the first trial to combine TCM syndrome differentiation with PD clinical stages and put it into clinical practice. The results of this trial will provide clinical evidence for the therapeutic effect of TCM formulas on PD patients of all stages and help build a new TCM treatment by stage model of PD. Trial registration : This trial is registered at the Chinese Clinical Trial Registry ( http://www.chictr.org.cn/ ). Registration number: ChiCTR2200056373, Date: 2022–02-04, version 1.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
乐乐乐乐乐乐应助小绵羊采纳,获得10
1秒前
2秒前
研友_5Z4ZA5完成签到,获得积分10
2秒前
5秒前
GU发布了新的文献求助20
5秒前
重要的天空完成签到 ,获得积分10
5秒前
hm完成签到,获得积分10
6秒前
上官凯凯完成签到 ,获得积分10
6秒前
xs发布了新的文献求助10
7秒前
9秒前
小绵羊完成签到,获得积分20
11秒前
小蘑菇应助GU采纳,获得20
12秒前
MS903完成签到 ,获得积分10
13秒前
fugdu完成签到,获得积分10
16秒前
18秒前
ww完成签到,获得积分10
18秒前
guantlv完成签到,获得积分10
19秒前
科研君不爱科研完成签到,获得积分10
21秒前
CJW完成签到 ,获得积分10
22秒前
YL关注了科研通微信公众号
23秒前
24秒前
上官若男应助fugdu采纳,获得30
25秒前
KSung完成签到 ,获得积分10
29秒前
Sylvia_J完成签到 ,获得积分10
29秒前
hyjcs完成签到,获得积分10
30秒前
陨落的繁星完成签到,获得积分10
31秒前
勤奋幻天完成签到 ,获得积分10
35秒前
35秒前
明理土豆完成签到 ,获得积分10
35秒前
神勇友灵完成签到,获得积分10
37秒前
forest完成签到,获得积分10
37秒前
38秒前
不安毛豆发布了新的文献求助10
38秒前
想想发布了新的文献求助10
40秒前
ding应助forest采纳,获得10
42秒前
汕头凯奇完成签到,获得积分10
43秒前
YL发布了新的文献求助10
43秒前
满意白卉完成签到 ,获得积分10
44秒前
充电宝应助不安毛豆采纳,获得10
47秒前
高分求助中
The Oxford Handbook of Social Cognition (Second Edition, 2024) 1050
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Handbook of Qualitative Cross-Cultural Research Methods 600
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3139659
求助须知:如何正确求助?哪些是违规求助? 2790543
关于积分的说明 7795637
捐赠科研通 2446993
什么是DOI,文献DOI怎么找? 1301553
科研通“疑难数据库(出版商)”最低求助积分说明 626264
版权声明 601176